Sanofi, Novo Spar In Insulin Pen Patent Suit—Again

Law360, New York (October 26, 2007, 12:00 AM EDT) -- Sanofi-Aventis has bulwarked its defenses against Novo Nordisk A/S and stepped up its demands for relief in their insulin pen spat with a dozen counterclaims, citing a licensing deal it said prevented Novo from suing and pointing to the company's history of crying wolf with patent suits it eventually withdraws.

Novo's suit, filed in the U.S. District Court for the District of New Jersey, accuses Sanofi's SoloStar pen of infringing its patent, U.S. Patent Number 7,241,278, for FlexPen, the top-selling insulin injection device in the U.S....
To view the full article, register now.

Law360 UK

UK Financial Services

Read Our Latest UK Legal News & Analysis

Financial Services Law360 UK and Insurance Law360 UK provide breaking news and in-depth analysis on U.K. and European Union regulation, enforcement, legislation, and litigation involving banks, investment firms, insurers, and more.